Consensus for antifungal stewardship in China (2024 edition)
Feng Ye,Shaoxi Cai,Bin Cao,Linling Cheng,Hong Fan,Yi Huang,Shanping Jiang,Guoxiang Lai,Yuping Li,Yi Shi,Danyang She,Xin Su,Kejing Tang,Hongmin Wang,Lingwei Wang,Bin Xu,Jinfu Xu,Jing Zhang,Jianquan Zhang,Tiantuo Zhang,Wei Zhang,Yunhui Zhang,Hua Zhou,Jianda Hu,Xiaojun Huang,Erlie Jiang,Qifa Liu,Jingbo Wang,Depei Wu,Xi Zhang,Yan Kang,Haibo Qiu,Bing Gu,Baoqing Sun,Yingchun Xu,Cunwei Cao,Ruoyu Li,Weihua Pan,Chao Zhuo,Liping Zhu,Haihui Huang,Rongsheng Tong,Mei Jiang,Jieming Qu
DOI: https://doi.org/10.21037/jtd-24-13
2024-06-30
Abstract:Background: Invasive fungal disease (IFD) has become a serious threat to human health in China and around the world, with high mortality and morbidity. Currently, the misdiagnosis rate of IFD is extremely high, compounded with the low quality of prescription antifungals and the high incidence of adverse events associated with IFD treatment, resulting in lengthy hospitalization, low clinical response, and high disease burden, which have become serious challenges in clinical practice. Antifungal stewardship (AFS) can not only significantly increase the early diagnosis rate of IFD, reduce inappropriate utilization of antifungal drugs, improve patient prognosis, but can also improve therapeutic safety and reduce healthcare expenses. Thus, it is urgent to identify key AFS metrics suitable for China's current situation. Methods: Based on metrics recommended by international AFS consensuses, combined with the current situation of China and the clinical experience of authoritative experts in various fields, several metrics were selected, and experts in the fields of respiratory diseases, hematology, intensive care units (ICUs), dermatology, infectious diseases, microbiology laboratory and pharmacy were invited to assess AFS metrics by the Delphi method. Consensus was considered to be reached with an agreement level of ≥80% for the metric. Results: Consensus was reached for 24 metrics, including right patient metrics (n=4), right time metrics (n=3), and right use metrics (n=17). Right use metrics were further subdivided into drug choice (n=8), drug dosage (n=4), drug de-escalation (n=1), drug duration (n=2), and drug consumption (n=2) metrics. Forty-six authoritative experts assessed and reviewed the above metrics, and a consensus was reached with a final agreement level of ≥80% for 22 metrics. Conclusions: This consensus is the first to propose a set of AFS metrics suitable for China, which helps to establish AFS standards in China and is also the first AFS consensus in Asia, and may improve the standard of clinical diagnosis and treatment of IFD, and guide hospitals to implement AFS, ultimately promoting the rational use of antifungal drugs and improving patient prognosis.